Trial Results Link Invokana Use to Foot and Leg Amputations
According to a new trial, Invokana has shown an increased risk of leg, foot, and toe amputations. The United States Food and Drug Administration is now releasing an alert to the public regarding the ongoing research involving the use of Invokana (canagliflozin) and lower-limb amputations. The type 2 diabetes drug is part of a drug class called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
The FDA recommends health care professionals to follow recommendations when prescribing Invokana and to properly monitor their patients. They should look for signs that would indicate a possible amputation such as new pain, sores, tenderness, ulcers, or infections in the lower legs. Other potential problems associated with Invokana use can be dizziness, frequent urination, dry mouth, and light headedness.
The European Medicines Agency (EMA) conducted a safety review of Invokana 100-mg, Invokana 300-mg, and a placebo. They determined that 7 in every 1,000 people taking the Invokana 100-mg experienced a toe amputation within one year. In comparison, 5 in every 1,000 people taking Invokana 300-mg experienced a toe amputation. The study analyzed about 2,000 type 2 diabetes patients.
If you or someone you love had a lower limb amputated after taking Invokana, you may be able to take legal action.
Our defective drug lawyers at Bailey Cowan Heckaman PLLC can protect your rights in a legal matter. We know how difficult it can be to deal with an amputation. You may be able to seek compensation for the damages you’ve sustained. Call us today to learn more about your rights.